Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of the circulating metabolite profile of PF-04991532, a hepatoselective glucokinase activator, across preclinical species and humans: potential implications in metabolites in safety testing assessment.
Sharma R, Litchfield J, Bergman A, Atkinson K, Kazierad D, Gustavson SM, Di L, Pfefferkorn JA, Kalgutkar AS. Sharma R, et al. Drug Metab Dispos. 2015 Feb;43(2):190-8. doi: 10.1124/dmd.114.061218. Epub 2014 Nov 10. Drug Metab Dispos. 2015. PMID: 25384899 Clinical Trial.
Metabolism and excretion of (S)-6-(3-cyclopentyl-2-(4-trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid (PF-04991532), a hepatoselective glucokinase activator, in humans: confirmation of the MIST potential noted in first-in-Human metabolite scouting studies.
Sharma R, Bergman A, Litchfield J, Atkinson K, Kazierad DJ, Kalgutkar AS. Sharma R, et al. Among authors: kazierad dj. Xenobiotica. 2019 Dec;49(12):1447-1457. doi: 10.1080/00498254.2019.1581960. Epub 2019 Mar 7. Xenobiotica. 2019. PMID: 30747552 Clinical Trial.
A 4-week study assessing the pharmacokinetics, pharmacodynamics, safety, and tolerability of the glucagon receptor antagonist PF-06291874 administered as monotherapy in subjects with type 2 diabetes mellitus.
Bergman A, Tan B, Somayaji VR, Calle RA, Kazierad DJ. Bergman A, et al. Among authors: kazierad dj. Diabetes Res Clin Pract. 2017 Apr;126:95-104. doi: 10.1016/j.diabres.2017.01.019. Epub 2017 Feb 3. Diabetes Res Clin Pract. 2017. PMID: 28237861 Clinical Trial.
Comparison of midazolam and simvastatin as cytochrome P450 3A probes.
Chung E, Nafziger AN, Kazierad DJ, Bertino JS Jr. Chung E, et al. Among authors: kazierad dj. Clin Pharmacol Ther. 2006 Apr;79(4):350-61. doi: 10.1016/j.clpt.2005.11.016. Epub 2006 Feb 28. Clin Pharmacol Ther. 2006. PMID: 16580903 Clinical Trial.
Effect of aging on atenolol pharmacokinetics and pharmacodynamics.
Sowinski KM, Forrest A, Wilton JH, Taylor AM 2nd, Wilson MF, Kazierad DJ. Sowinski KM, et al. Among authors: kazierad dj. J Clin Pharmacol. 1995 Aug;35(8):807-14. doi: 10.1002/j.1552-4604.1995.tb04124.x. J Clin Pharmacol. 1995. PMID: 8522638
26 results